What's Going On With Lifeway Stock After Rejecting Revised Acquisition Offer From Danone? Lifeway Foods, Inc. (NASDAQ:LWAY) shares are trading lower on Wednesday after the company’s Board of Directors rejected a revised unsolicited acquisition proposal from Danone North America PBC. The proposal on November 15 offered $27.00 per share to acquire all of Lifeway’s shares that Danone does not already own. After careful evaluation, including consultations with independent financial and legal advisors, the Lifeway Board determined that the offer significantly undervalued the company and was not in the best interests of Lifeway’s shareholders or other stakeholders. According to a recent Schedule 13D amendment filing, Danone beneficially owns approximately 23.3% of Lifeway’s outstanding common stock. On November 5, 2024, Lifeway announced that its Board had rejected Danone’s initial unsolicited, non-binding proposal of $25.00 per share, citing that it substantially undervalued the company. Lifeway said it remains committed to its strategic plan of expanding its kefir offerings while also branching into adjacent product categories. Also Read: Target Q3 Earnings: Supply Chain Chaos Hits Bottomline, Slashes Annual Profit Outlook, Stock Tanks The company reported growth in its third-quarter 2024 results, achieving its 20th consecutive quarter of growth with double-digit year-over-year revenue growth and improved profit margins. Lifeway said it generated a total shareholder return of 788% over the past five years, vastly outperforming its food and beverage industry peers and the S&P 500. In line with its growth momentum, Lifeway has also announced the launch of a new functional beverage: Probiotic Smoothie + Collagen made with kefir cultures. This product comes in four flavors—Matcha Latte, Berry Blast, Tropical Fruit, and Plain—and contains 5 grams of collagen per serving. It is also lactose-free, capitalizing on the growing consumer demand for lactose-free dairy alternatives. According to Benzinga Pro, LWAY stock has gained over 56% in the past year. Price Action: LWAY shares are trading lower by 5.72% to $23.89 at last check Wednesday. Photo via Shutterstock Read Next: Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines? Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? LIFEWAY FOODS (LWAY): Free Stock Analysis Report This article What's Going On With Lifeway Stock After Rejecting Revised Acquisition Offer From Danone? originally appeared on Benzinga.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. View Comments
What's Going On With Lifeway Stock After Rejecting Revised Acquisition Offer From Danone?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...